Roche is a pharmaceutical and diagnostics company that focused on improving people’s lives. Roche Holding AG is the owner of F. Hoffmann-La Roche Ltd., a provider of in-vitro diagnostics and drugs for cancer and transplantation. It specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. F. Hoffmann-La Roche Ltd. serves hospitals, research labs, private medical labs, practicing physicians, and patients. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. F. Hoffmann-La Roche Ltd. also conducts research and development as well as production-related to molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostics and research. Roche was established in 1896 and is based in Basel, Switzerland.

Research Grants 187 show all


$79.2M
2016

$70.6M
2017

$157.8M
2018

$44.4M
2019

$3.9M
2020

Publications 780 show all

  • 25
    Escherichia coli/genetics
  • 24
    Proto-Oncogene Proteins/genetics
  • 24
    Transcription, Genetic
  • 23
    Escherichia coli Proteins
  • 21
    Carrier Proteins/metabolism
  • 21
    DNA Replication
  • 19
    Genes
  • 18
    Calcium/metabolism
  • 18
    DNA-Binding Proteins/genetics
  • 18
    Gene Expression Regulation

Patents 99,551show all

  • 20,355
    C07D - Heterocyclic compounds
  • 9,172
    A61K - Preparations for medical, dental, or toilet purposes
  • 7,944
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 7,931
    C07C - Acyclic or carbocyclic compounds
  • 5,025
    C07K - Peptides
  • 3,669
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 2,598
    C12N - Microorganisms or enzymes
  • 2,479
    A61B - Diagnosis
  • 2,075
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 1,611
    Y02P - Climate change mitigation technologies in the production or processing of goods

Clinical Trials 5,461show all

1,839Phase 31,279N/A899Phase 2514Phase 1327Phase 4199Other

Contact Information

Konzern-Hauptsitz Grenzacherstrasse 124
Basel 4070
Switzerland

Overview

Total FundingEmployeesLast Funding DateStatus
$2,790,000,00010000+2010-01-01Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2010-01-01Undisclosed
2001-05-08$2,790,000,000Post Ipo EquityNovartis